Business
BioAtla is a clinical-stage biopharmaceutical company developing conditionally active biologic antibody therapies for solid tumor cancers.
BioAtla narrowed losses and improved cash burn, but remained pre-revenue with equity turning negative.
The read at a glance✓ Audited against SEC data
- Business mix — Conditionally active antibody oncologyNote
- Revenue — No core revenue reportedNote
- Losses — Net loss narrowed 14.6%OK
- Cash — Cash from ops improvedOK
- Balance sheet — Equity turned negativeWatch
- Insiders — 0 purchases / 0 salesNote
- Accounting — Altman-Z, Beneish-M, and earnings-quality unavailable for FY2025Note
Latest filings
- 8-K · Company announcement2026-08-28
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-07-16
- DEF 14A · Annual proxy (pay & governance)2026-06-03
- 10-Q · Quarterly report2026-05-15
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about BioAtla, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.